Sunshine Biopharma Dividend

Dividend criteriumcontroles 0/6

Sunshine Biopharma does not have a record of paying a dividend.

Belangrijke informatie

n/a

Dividendrendement

-95.0%

Terugkoop Rendement

Totaal aandeelhoudersrendement	-95.0%
Toekomstig dividendrendement	n/a
Dividendgroei	n/a
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	n/a

Recente dividendupdates

Geen updates

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Insufficient data to determine if SBFM's dividends per share have been stable in the past.

Groeiend dividend: Insufficient data to determine if SBFM's dividend payments have been increasing.

Dividendrendement versus markt

Sunshine Biopharma Dividendrendement versus markt

Hoe verhoudt SBFM dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (SBFM)	n/a
Markt onderkant 25% (US)	1.5%
Markt Top 25% (US)	4.5%
Gemiddelde industrie (Biotechs)	2.2%
Analist prognose (SBFM) (tot 3 jaar)	n/a

Opmerkelijk dividend: Unable to evaluate SBFM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hoog dividend: Unable to evaluate SBFM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Winstuitkering aan aandeelhouders

Verdiendekking: Insufficient data to calculate SBFM's payout ratio to determine if its dividend payments are covered by earnings.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Unable to calculate sustainability of dividends as SBFM has not reported any payouts.

Sunshine Biopharma Dividend

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente dividendupdates

Recent updates

Sunshine Biopharma, Inc., Annual General Meeting, Dec 10, 2024

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Share price stability

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023

Sunshine Biopharma Receives 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding

First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022)

Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces an Equity Buyback for $2 million worth of its shares.

Sunshine Biopharma Receives Non-Compliance Notice From Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) completed the acquisition of Nora Pharma Inc. from Malek Chamoun.

Sunshine Biopharma acquires Nora Pharma for C$30M

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: US$0.034 loss per share (vs US$1.20 loss in 2Q 2021)

Sunshine Biopharma reports 1H results

First quarter 2022 earnings released: US$0.23 loss per share (vs US$2.82 loss in 1Q 2021)

Sunshine Biopharma, Inc. Files Patent Application Announces mRNA Molecules

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Sunshine Biopharma, Inc.’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

Less than half of directors are independent

Sunshine Biopharma Common Stock Deleted from Other OTC

Sunshine Biopharma Mice Study for Covid-19 Treatment Progressing as Planned

Sunshine Biopharma, Inc.’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types

Sunshine Biopharma, Inc. announced that it has received $0.5 million in funding from RB Capital Partners, Inc.

Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend